ViroGates A/S Market Cap ($10.89 Million)
Market Cap & Net Worth: ViroGates A/S (VIRO)
ViroGates A/S market cap. ViroGates A/S (CO:VIRO) has a market capitalization of $10.89 Million (Dkr69.61 Million) as of November 1, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #26734 globally and #124 in its home market, demonstrating a -6.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ViroGates A/S's stock price Dkr7.50 by its total outstanding shares 9281891 (9.28 Million). Also see cash efficiency ratio of ViroGates A/S for how efficiently the company converts equity into cash flow.
ViroGates A/S Market Cap History (2018–2026)
ViroGates A/S market cap history from 2018 to 2026. Data shows change from $87.13 Million to $10.89 Million (-25.28% CAGR). Check VIRO stock price and chart for real-time trading data and today's change.
ViroGates A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ViroGates A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore VIRO net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.68x
ViroGates A/S's market cap is 3.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $87.13 Million | $3.32 Million | -$16.99 Million | 26.28x | N/A |
| 2019 | $49.81 Million | $3.58 Million | -$18.80 Million | 13.91x | N/A |
| 2020 | $118.36 Million | $5.35 Million | -$18.74 Million | 22.11x | N/A |
| 2021 | $209.12 Million | $7.66 Million | -$17.66 Million | 27.31x | N/A |
| 2022 | $58.23 Million | $15.20 Million | -$9.65 Million | 3.83x | N/A |
| 2023 | $8.74 Million | $6.99 Million | -$12.10 Million | 1.25x | N/A |
| 2024 | $15.39 Million | $4.90 Million | -$14.35 Million | 3.14x | N/A |
| 2025 | $19.53 Million | $5.31 Million | -$10.40 Million | 3.68x | N/A |
Competitor Companies of VIRO by Market Capitalization
Companies near ViroGates A/S in the global market cap rankings as of November 1, 2026. Also see balance sheet size of ViroGates A/S for a full breakdown of the balance sheet.
Key companies related to ViroGates A/S by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $184.67 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #215 globally with a market cap of $111.95 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #225 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $184.67 Billion | $106.20 |
| #215 | Stryker Corporation | NYSE:SYK | $111.95 Billion | $291.86 |
| #225 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $96.54 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of ViroGates A/S (2018–2026)
Market capitalization of ViroGates A/S from 2018 to today. Between 2018 and today, ViroGates A/S's market cap moved from $87.13 Million to $ 10.89 Million, with a yearly change of -25.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr10.89 Million | -44.24% |
| 2025 | Dkr19.53 Million | +26.89% |
| 2024 | Dkr15.39 Million | +76.08% |
| 2023 | Dkr8.74 Million | -84.99% |
| 2022 | Dkr58.23 Million | -72.15% |
| 2021 | Dkr209.12 Million | +76.69% |
| 2020 | Dkr118.36 Million | +137.61% |
| 2019 | Dkr49.81 Million | -42.83% |
| 2018 | Dkr87.13 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of ViroGates A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.89 Million USD |
| MoneyControl | $10.89 Million USD |
| MarketWatch | $10.89 Million USD |
| marketcap.company | $10.89 Million USD |
| Reuters | $10.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measur… Read more